Introduction
One of the hallmarks of cancer is evasion of apoptosis (1) that is often promoted by the dysregulation of pro-and anti-apoptotic Bcl-2 family proteins (2) . The expression of Bax or Bak appears to play a key role in suppressing cancer development and decreased Bax levels have been observed in a number of cancers (3) (4) (5) . In addition, Bax protein levels are further reduced in advanced chronic lymphocytic leukemia (CLL) and contribute to chemoresistance in this disease (6) (7) (8) (9) . Several studies have revealed that Bax has a shortened half-life and low expression in cancer cells due to its abnormal increased degradation by the ubiquitin-proteasomal pathway (3, 8, 9) .
Enhanced proteasomal degradation of Bax appears to be clinically relevant as it is most evident in the advanced stages of prostate cancer (3) , and is correlated with poor prognosis in CLL (8) .
Reduced expression and stability of Bax may also have immunological consequences. We hypothesized that the enhanced proteasomal degradation of Bax in cancer cells would generate peptides that can be presented by MHC class I molecules at the cell surface. By contrast, in healthy tissue Bax has a long half-life and is predominantly localized in the cytosol or loosely attached to outer mitochondrial membranes (10, 11) . Normal expression and function of Bax is regulated by interactions with other members of the BCL2 family (12) rather than proteasomal degradation. So we would not expect significant quantities of Bax-derived peptides to be presented by MHC class I molecules in healthy cells. Thus, the degraded forms (peptides) of Bax in cancer cells could potentially serve as tumor-specific antigens.
Other proteins involved in apoptosis have been proposed as tumor antigens (13) , based on over-expression in cancer cells. Here we test the possibility that Bax, a
Materials and Methods

Blood samples
Healthy volunteer blood samples were collected locally and CLL samples were derived from clinics at the University Hospital of Wales and Llandough Hospital. All samples were collected with informed consent with ethical approval (South East Wales Research Ethics Committee (02/4806)). Peripheral blood mononuclear cells (PBMC) were isolated by Histopaque-1077 (Sigma) centrifugation, as previously described (15) .
Cell lines
The following were purchased from ATCC: CaSki, HepG2, U2OS and SAOS and passaged according to ATCC protocols within 6 months. The ATCC authenticates cell lines by DNA fingerprinting (STR analysis). The remaining cell lines used were not authenticated according to AACR guidelines but were assessed regularly (where appropriate) for EBV genes, HPV genes, HLA class I and morphology. These were provided by: BJAB, DG175, BV173 (Prof. M. Rowe via MRC Tissue Culture Facility, Cardiff); DU145 (Prof. W. Jiang, Cardiff); MDA231 (Prof L. Sherman, La Jolla); SK29mel and TK143 (Prof. Cerundolo, Oxford); C33A and C33A-HPV16 (Prof. Dillner, Malmo). Primary skin fibroblasts were obtained from healthy donors as described (14) . SiHa-A2 (15), T2 and K562 cells were from laboratory stocks. All cell lines used were mycoplasma negative.
Bax peptides
Twenty-three candidate peptides were identified from the amino acid sequence of Bax using predictive computer algorithms for HLA binding. Fourteen peptides were predicted to bind to HLA-A*0201, with others to HLA-A3, HLA-B7, HLA-A1, HLA-B8 or HLA-B44 (supplemental data, Table S1 ). Individual Bax peptides (601-623, Mimotopes) were dissolved in DMSO. Aliquots from these stock peptides were pooled (Bax pool 601-23) and stored at -80ºC. Smaller pools of 6-9 peptides were made for epitope mapping. Higher purity peptides Bax p613 (96.4%) and p610 (95.7%) were synthesized (ProImmune) for dose-response experiments.
T2 binding assay
Peptide binding was determined by upregulation of HLA-A2 expression on T2 cells as previously described (15) . Briefly, 10 5 T2 cells were incubated with 50µg/ml peptide in serum-free RPMI overnight at 37 o C. Upregulation of surface HLA-A2 was assessed by flow cytometry using MA2.1 antibody (IgG1, HLA-A2 specific, ATCC).
HLA-A2 increase was calculated as follows: % Increase = [(mean fluorescence with peptide -mean fluorescence without peptide)/ mean fluorescence without peptide x100].
Induction of Bax-specific T cells
PBMC were immunomagnetically enriched for CD8 + T cells with anti-CD8 microbeads according to the manufacturer's instructions (Miltenyi Biotec). After enrichment (>90% CD8 + ), T cells were re-suspended at 2-2.5 x 10 6 cells/ml in RPMI-1640 (Sigma) supplemented with 5% human AB serum, 2 mM glutamine, 100 µg/ml streptomycin, 100 U/ml penicillin and 25 mM HEPES (AB-RPMI). The cells were cultured with Bax peptide pool (10µg/ml), irradiated autologous PBMC, 10 IU/ml rIL-2 (Proleukin), 1μg/ml CD28 (Beckman Coulter) and 0.5μg/ml CD49d antibodies (Serotec). Following 3 days of incubation, 1ml AB-RPMI media, supplemented with 40 IU/ml recombinant IL-2, was added to each well. T cell cultures were restimulated weekly with the peptide pool with autologous PBMC APC. On day 28, T cells were harvested and tested in ELISpot assays. 
Isolation and cloning of peptide-specific T cells
ELISpot assay
These were performed as previously described (17) . For detection of peptide-specific responses, cultured T cells were plated out in triplicate at 10 5 (initial screen) or 1-2x10 4 cells (clones/lines) per well. Assay wells were either T cells incubated with APC, or APC plus Bax peptides (10 µg/ml). APC were added to T cells at 1:1 ratio. T cells were also incubated with no APC (negative control) or with mitogens (17) (positive control). The number of spots/well was counted using an inverted stereomicroscope (8x magnification) and verified with an ELIspot reader (AID ,Cadama). The specific peptide response was calculated by subtracting the background response (T cells+APC) from the T cells+APC+peptide wells.
Chromium-51 ( 51
Cr) release cytotoxicity assays
The cytotoxic activity of Bax specific T cells was tested in 51 Cr release assays as previously described (16 (0041HA, IgG2b, One Lambda) were used for controls.
LiveCount killing assay
The cytotoxicity of Bax specific T cells against primary CLL cells was assessed using a modified flow cytometry based assay (18 
Western blotting
Cells were resuspended in 50 µl PBS per 10 6 cells, and test samples prepared as previously described (19) . Proteins were then separated by SDS-PAGE and transferred onto PVDF membranes (Amersham Biosciences) for immunoblotting using a chemiluminescent detection protocol (19) . Specific antibody-protein complexes were detected using alkaline phosphatase-conjugated secondary antibodies 
Results
Peptide binding assay
Fourteen peptides with predicted binding to HLA-A2 were tested in the T2 peptidebinding assay. Of these, only four peptides showed measurable binding to HLA-A2 molecules (Supplementary Table S1 ). Bax p614 (ALCTKVPEL) was the strongest HLA-A2 binding peptide (150% increase) followed by Bax p613 (IMGWTLDFL, 115% increase). Bax p612 (KLSECLKRI) and p610 also exhibited binding (49% and 5% respectively). Based on their HLA-A2 binding, only these four Bax peptides would be predicted to be candidate T cell epitopes. However we included all the candidate HLA-A2 peptides in subsequent experiments because we have previously demonstrated that even peptides with poor or low binding in the T2 assay can be T cell epitopes (16, 20) . Peptide dose response experiments confirmed that KSIVB17 could recognize both Bax peptides at high peptide concentrations (10-0.1 µM), but had greater avidity for the p613 nonamer as shown by the amount of peptide required for 50% maximal lysis (0.5 nM for p613 vs 10.9 nM for p610, Figure 1D ). These results, together with the T2 peptide binding data (Supplementary Table S1 ), suggest that the Bax p613 sequence (IMGWTLDFL) is the optimum epitope for KSIVB17 T cells.
Bax peptide-specific T cell responses detected in healthy donors
Bax-specific T cells can kill a range of human tumor cells
The underlying hypothesis for this study was that abnormal proteasomal degradation of Bax protein should generate peptides that bind to HLA class I for presentation to ). There was no obvious connection between target cell lysis and HLA-A2 + expression (Table 1) .
Since Bax protein is also expressed in normal, non-transformed cells, KSIVB17 T cells were tested for cytotoxicity against autologous and allogeneic healthy PHA blasts, and allogeneic healthy skin fibroblasts. KSIVB17 did not induce specific lysis of either autologous or allogeneic PHA blasts ( Figure 2A ). However, there was lysis when the Bax p613 was added exogenously to the HLA-A2 + PHA blasts demonstrating that these targets were competent at presenting HLA-A2 binding peptides. No specific lysis by KSIVB17 was observed against two HLA-A2 + allogeneic skin fibroblasts ( Figure 2B ). NK cell-like activity was also excluded since KSIVB17 T cells did not kill NK-sensitive K562. Specific killing was seen only against Bax p613-pulsed T2 cells ( Figure 2B ). These results indicate that specific killing by KSIVB17 is directed against tumor cells and not healthy non-transformed cells. 
It was possible that the killing of allogeneic tumor cells was not mediated by Bax peptide-specific T cells, but by subpopulations of alloreactive T cells (21) or T cells with unknown specificity. Therefore to confirm the antigenic specificity and MHC restriction of tumor cell killing, cold-target competition and monoclonal antibody blocking assays were performed. KSIVB17 killing of labeled (hot) TK143 target cells was decreased in a Cold:Hot target ratio-dependent manner, whereas unlabeled T2 alone or T2 pulsed with Flu M1 58-66 peptide showed no effect on TK143 target lysis ( Figure 3A) . Similar cold target inhibition of KSIVB17 cytotoxicity against "hot" C33A-HPV16 targets was also observed ( Figure 3B ). These results indicate that killing of the TK143 and C33A-HPV16 tumor cell targets was specifically mediated by Bax p613-specific CTL. 
inhibition of peptide-pulsed target T2 cells was seen, ruling out any non-specific toxicity effect ( Figure 4A ). Using C33A-HPV16 target cells, the inhibitory effects of bortezomib were seen to be potent at concentrations as low as 0.001 µM ( Figure 4B ). proteasome inhibitor ( Figure 5B ). There was however, some donor variation, for example an increase in Bax 21 kDa expression was seen in HD7 and HD8 ( Figure 5B , Supplementary Table S3 ). There was also some weak but detectable increase in the Bax 18 kDa cleavage product in some samples e.g. HD1 ( Figure 5B , Supplementary   Table S3 ). But, overall there was no significant increase in the Bax 18 kDa expression levels after proteasome inhibitor treatment in healthy donors (Supplementary Figure   S2 ). This data indicates that there is enhanced proteasomal degradation of Bax in tumor cells compared to non-transformed cells.
Bax peptide-specific T cells recognize primary malignant cells from CLL patients
The KSIVB17 T cell clone was shown to kill human cancer cell lines, and this appeared to correspond with proteasomal degradation of Bax. However, such established cell lines might not be representative of primary cancer cells. For ethical and practical reasons it was not possible to obtain primary epithelial cancer tissue from patients. Therefore we tested primary cancer cells obtained from patients with a haematological malignancy, CLL. This was based on previous reports that Bax was targeted by the ubiquitin-proteasome pathway in CLL (9) , and this activity was correlated with poorer clinical prognosis (8) . As a prelude to T cell assays, the expression of Bax after treatment with proteasome inhibitor lactacystin was assessed in primary samples obtained from 13 CLL patients. There was an increased expression (1.5 to 2.4 fold) of the Bax 21 kDa form after lactacystin treatment in 3/13 patients (Supplementary Table S4 ), but overall this was not significantly different to 
Discussion
There has been an intense drive to define human tumor antigens for use in immunotherapy and as surrogate markers of anti-tumor immunity. Human tumor antigens can be divided into several overlapping categories including but not restricted to: cancer testis antigens (25) , oncogenic viral antigens (26) and tissue specific antigens (27) . There is also a category of human tumor antigens based on proteins that have a low expression in normal tissue but have over-expression in cancers (28, 29) . Here we define a novel epitope derived from Bax that is presented to T cells on variety of human cancer cells, including primary CLL cells. We propose that this epitope is derived from proteasomal degradation of Bax, a process that is absent or occurring at lower levels in normal cells. This represents the first definition of a human tumor epitope based on enhanced proteasomal degradation as opposed to over expression of protein in cancer cells.
The enhanced proteasomal degradation of key regulatory proteins contributes to the malignant phenotype in several human cancers (30) (31) (32) (33) . In this study, Bax was chosen as a potential tumor target because decreased protein stability and expression had been correlated with cancer progression (3) or poorer clinical prognosis (8) .
Decreased stability and/or increased proteasomal degradation of intracellular proteins can also have immunological consequences. For example, CTL recognition of endogenously processed proteins can be governed by instability or susceptibility to degradation, rather than high levels of protein expression (34) (35) (36) (37) (38) . Enhanced T cell recognition of epitopes from p53 appears to correlate with low p53 expression, as a result of increased degradation (37, 38) . Our results suggest that a similar effect is occurring with Bax in cancer cells. 
Mass spectrometry has been used to detect the presence of tumor-specific peptides presented by MHC class I molecules (39) but requires large-scale culture of cancer cells. Therefore, we tested our hypothesis by using T cells as sensitive probes epitope defined from the Bax-α protein. However, T cell epitopes from the Bax-δ isoform have also been defined (40) . Those epitopes were distinct from the ones investigated in the current study and by contrast to Bax-α the functional significance of the δ isoform remains unclear (41) .
Allogeneic hematopoetic stem cell transplants have the potential to be curative for a subset of CLL patients based on the T cell-mediated graft versus leukemia effect (42) . On the basis of our results, we propose that peptides from Bax could serve as T cell targets in CLL. This is an attractive concept because Bax instability is more common in poor prognosis CLL patients (8) . In preliminary experiments in CLL patients (n=6), we have been unable to directly detect memory T cells against Bax p613 using tetramers (data not shown). Although further experiments are needed, this was not entirely surprising, because it is well documented that CLL cells are poor APC and exert potent immunosuppression (42) . Thus it has proved difficult to detect T cell responses against any tumor antigens, even in vaccinated patients (43) Cr release assays. The EC 50 value was calculated using the fitted curve. The % specific lysis from 51 Cr release assays shown is an average of at least duplicate experiments at an E:T ratio of 40-50:1. The results considered as positive killing (>20% lysis) are in bold.
# HLA-A2
Mean Fluorescence Intensity as measured by flow cytometry using MA2.1 antibody, nil= no expression. Representative graphs showing lysis of targets over a full range of E:T ratios can be seen in Supplemental figure S1 . 
